• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Brentuximab Vedotin Yields Modest Response in Relapsed Diffuse Large B-Cell Lymphoma

by
November 20, 2026
in Health
Reading Time: 4 mins read
0
Brentuximab Vedotin Yields Modest Response in Relapsed Diffuse Large B-Cell Lymphoma

Brentuximab Vedotin Yields Modest Response in Relapsed Diffuse Large B-Cell Lymphoma

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A systematic review and meta-analysis published in the Annals of Hematology indicates that brentuximab vedotin regimens offer modest and heterogeneous therapeutic activity in patients diagnosed with relapsed or refractory diffuse large B-cell lymphoma. Diffuse large B-cell lymphoma, commonly designated as DLBCL, remains a demanding clinical challenge, particularly after patients fail initial standard R-CHOP therapy. While chimeric antigen receptor T-cell therapies have notably enhanced clinical outcomes for qualifying individuals, broader therapeutic utility is frequently restricted by high treatment costs, logistical obstacles, and pronounced toxicity profiles. Seeking to evaluate alternative interventions, researchers examined brentuximab vedotin, an antibody-drug conjugate directed against CD30 that has exhibited targeted anti-tumor activity across select CD30-positive lymphoid malignancies.

To rigorously aggregate existing clinical evidence, the investigative team executed comprehensive database searches across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from their respective inception dates up to January 2026. Their identification process selected five distinct clinical studies comprising six treatment cohorts and encompassing an aggregate population of 260 patients. The primary efficacy synthesis concentrated specifically on individuals treated for relapsed or refractory DLBCL, a subset representing two included studies, three distinct treatment cohorts, and 173 evaluable patients. Complementary sensitivity analyses subsequently incorporated an additional cohort of patients diagnosed with relapsed or refractory primary mediastinal B-cell lymphoma, followed by an expanded meta-analysis that integrated all identified treatment cohorts, including frontline and mixed patient populations.

The quantitative synthesis protocol derived pooled proportions for complete response rates and overall response rates using single-arm statistical methodologies. Investigators conducted model fitting within R software version 4.5.2 employing the metafor package, applying random-effects models to integrate outcome data across the disparate patient groups. Between-study statistical heterogeneity was formally assessed and quantified using the standard I-squared statistic. In addition, the authors executed leave-one-out sensitivity analyses to systematically test the numerical stability and robustness of the resulting pooled efficacy and safety proportions.

Among the primary evaluable cohorts restricted strictly to relapsed or refractory DLBCL, brentuximab vedotin regimens yielded a pooled overall response rate of 0.53, corresponding to a 95 percent confidence interval spanning from 0.25 to 0.79 with an I-squared heterogeneity measure of 68.6 percent. Within this identical primary subpopulation, the pooled complete response rate reached 0.25, accompanied by a wide 95 percent confidence interval extending from 0.05 to 0.69 and an I-squared heterogeneity calculation of 79.3 percent. These findings demonstrate that approximately one in two patients showed measurable clinical responses, while approximately one in four attained a complete disappearance of detectable disease under the evaluated regimens.

Subsequent sensitivity analyses demonstrated that pooled efficacy estimates shifted noticeably when broader histological and line-of-treatment groups were merged into the calculation. Incorporating the relapsed or refractory primary mediastinal B-cell lymphoma cohort shifted the calculated complete response rate to 0.29, with a 95 percent confidence interval between 0.12 and 0.56, while the overall response rate adjusted to 0.58, with a 95 percent confidence interval of 0.35 to 0.78. When investigators pooled all six treatment cohorts together—a combination incorporating frontline cohorts and mixed patient populations alongside refractory cohorts—the aggregate statistical estimates rose further, producing an overall complete response rate of 0.43 and an overall response rate of 0.65 across the entire dataset.

The evaluation of clinical safety endpoints across all included cohorts revealed substantial treatment-emergent hematologic toxicities. Severe adverse events overall were documented in 76 percent of patients across the pooled study cohorts, bounded by a 95 percent confidence interval of 0.51 to 0.90 and an I-squared heterogeneity value of 84.3 percent. Specific hematologic assessments showed that grade 3 or 4 neutropenia emerged in 40 percent of individuals, with a 95 percent confidence interval of 0.34 to 0.47. Grade 3 or 4 anemia was reported in 15 percent of patients, with a 95 percent confidence interval of 0.02 to 0.64, and grade 3 or 4 thrombocytopenia manifested in 12 percent, spanning a 95 percent confidence interval of 0.01 to 0.68.

Non-hematologic toxicities, treatment terminations, and patient fatalities formed an additional critical component of the systematic safety profile. Severe peripheral neuropathy classified as grade 3 or 4 was relatively uncommon, occurring at a pooled proportion of 0.07 with a 95 percent confidence interval from 0.04 to 0.14. Adverse events prompted permanent discontinuation of therapy in 18 percent of participating patients, with an estimated confidence interval from 0.07 to 0.39, while reported deaths occurring across the observed study period reached a pooled proportion of 10 percent, carrying a 95 percent confidence interval of 0.06 to 0.17.

When safety evaluation was restricted solely to the relapsed or refractory DLBCL cohorts, severe adverse events were recorded in 80 percent of patients, reflecting 128 affected individuals out of 161 evaluable subjects. Based on these observed clinical patterns, the authors concluded that brentuximab vedotin regimens confer modest, variable anti-lymphoma activity in relapsed or refractory DLBCL that is tempered by considerable hematologic adverse events. Because only two studies specifically enrolled relapsed or refractory DLBCL patients and the available body of evidence relies largely on non-randomized designs, the researchers emphasized that these findings remain strictly hypothesis-generating, mandating confirmation in rigorous randomized trials accounting for CD30 expression and supportive care.

Subject of Research: Systematic review and meta-analysis of brentuximab vedotin regimens in relapsed or refractory diffuse large B-cell lymphoma

Article Title: Efficacy and safety of brentuximab vedotin in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis

Article References: Khan, S., Khaliq, S., Hanzala, M., Khan, Z., Masood, S., Abedin, Z. U., Abideen, Z. U., Khair, A. N., Fatima, N., Shahid, I. F., Tahir, M. Z., Khalid, H. B., & Amin, M. H. J. (2026). Efficacy and safety of brentuximab vedotin in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis. Annals of Hematology. https://doi.org/10.1007/s00277-026-07370-w

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07370-w

Keywords: brentuximab vedotin, diffuse large B-cell lymphoma, relapsed refractory lymphoma, antibody-drug conjugate, CD30-positive lymphomas, systematic review, meta-analysis, complete response rate, overall response rate, hematologic toxicity, neutropenia, thrombocytopenia, peripheral neuropathy, primary mediastinal B-cell lymphoma, Annals of Hematology, random-effects model

News Source: Nathaniel Bowman. (November 20, 2026). Brentuximab Vedotin Yields Modest Response in Relapsed Diffuse Large B-Cell Lymphoma. Scienmag.

Tags: Annals of HematologyAntibody-drug conjugatebrentuximab vedotinCD30-positive lymphomascomplete response ratediffuse large B-cell lymphomahematologic toxicityMeta-analysisneutropeniaoverall response rateperipheral neuropathyprimary mediastinal B-cell lymphomarandom-effects modelrelapsed refractory lymphomasystematic reviewThrombocytopenia
Share12Tweet7Share2ShareShareShare1

Related Posts

Two-Drug Regimens Match Traditional HIV Therapy While Reducing Cumulative Drug Burden

Two-Drug Regimens Match Traditional HIV Therapy While Reducing Cumulative Drug Burden

November 20, 2026
Systematic Review Reveals Methodological Inconsistencies Across Neglected Tropical Disease Research Prioritization

Systematic Review Reveals Methodological Inconsistencies Across Neglected Tropical Disease Research Prioritization

November 20, 2026

MapMe Intervention Versions Show Potential Cost-Effectiveness In English Child Measurement Trial

November 20, 2026

Clinical Report Details Fatal and Recovered Cases of Accidental Aconitine Poisoning

November 20, 2026

POPULAR NEWS

  • Hybrid PET-MRI Motion Correction Enables High-Resolution Cardiac Disease Quantification

    Hybrid PET-MRI Motion Correction Enables High-Resolution Cardiac Disease Quantification

    29 shares
    Share 12 Tweet 7
  • Microbiota Shifts Interact With Host Methylation and TP53 Mutations in Gastric Cancer

    29 shares
    Share 12 Tweet 7
  • Cardiac Imaging Links Heart Markers to Quality of Life in DMD Carriers

    29 shares
    Share 12 Tweet 7
  • Study Links 18p Chromosomal Deletions to Reproductive and Endocrine Anomalies

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Two-Drug Regimens Match Traditional HIV Therapy While Reducing Cumulative Drug Burden

AeroCat Robotic Platform Advances Autonomous Surface Navigation and UAV Collaboration

Systematic Review Reveals Methodological Inconsistencies Across Neglected Tropical Disease Research Prioritization

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.